Gapping down
In reaction to disappointing earnings/guidance:
- GME -2.6%, ASND -2.2%, OXM -1.1%
Other news:
- ZSAN -34.5% (after filing a Form EFFECT (Notice of Effectiveness) for an S-1 offering)
- MNOV -16.6% (announces that the Phase 2 clinical trial of MN-166 in methamphetamine dependence did not meet the primary endpoint of methamphetamine abstinence confirmed via urine drug screens during the final two weeks of treatment)
- ACXM -10.9% (Acxiom announces change to Facebook (FB) relationship, says FY18 revenue and EPS guidance remain unchanged, sees FY19 revenues and profitability impacted by as much as $25 mln)
- HRTX -3.8% (prices offering of 6 mln shares of common stock at $26.00)
- OPBK -2% (after closing near highs on first day of Nasdaq IPO)
Analyst comments:
- GME -3.3% (downgraded to Underperform from Neutral at BofA/Merrill)
- CLD -3.3% (downgraded to Underweight from Neutral at JPMorgan)
- DUK -1.2% (downgraded to Sell from Neutral at Goldman)
- SBUX -1% (downgraded to Neutral from Outperform at Wedbush)
![]()